01
Latest News/ Blog
Gene Solutions & ATC introducing Oncology Portfolio in Turkey at the 2nd International Hereditary Cancers Congress with Industry Symposium & Oral Presentation
At the 2nd International Hereditary Cancers Congress (IHCC) held in Antalya, Turkey (February 5–8, 2026), Gene Solutions – co-hosted with its Turkey’s distribution partner – ATC – organized a dedicated
Cost & Insurance Coverage for MCED Tests in Singapore
This article is for educational purposes only. It does not provide specific pricing, promotions, or purchasing recommendations. Instead, it explains the general cost structure of ctDNA-based MCED tests and current insurance coverage considerations, including
From Recurrence to Resistance: Real-World Performance of a Hybrid ctDNA Assay in Breast Cancer Management
Penang, Malaysia – At the 14th Asia-Pacific Breast Cancer Summit (APBCS) 2026, Gene Solutions presented real-world data on K-TRACK, a novel hybrid circulating tumor DNA (ctDNA) testing approach. This integrative
From Basic Testing to an AI-Powered Comprehensive NIPT Ecosystem: Shaping the Future of Prenatal Care in India
NEW DELHI, INDIA — At the 68th All India Congress of Obstetricians and Gynecologists (AICOG 2026), Gene Solutions India hosted an industry session titled “Comprehensive Prenatal Screening for Better Maternal–Fetal Outcomes.” The session brought together
World Cancer Day 2026 – 1,000 MCED Tests for Early Detection
Early detection saves lives—but access must reach everyone. In conjunction with World Cancer Day 2026, Gene Solutions Malaysia and the National Cancer Society Malaysia (NCSM) officially signed a Memorandum of
World Cancer Day: Genomics & AI Blood Test Detects Cancer Before Symptoms Appear in India
PRESS RELEASE As late-stage cancer diagnosis continues to drive mortality and financial distress in India, Gene Solutions and Global Cancer Care highlight the role of early detection and patient navigation
Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.
IRVINE, Calif. — January 21, 2026 — Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed
The MCED Test experience
The experience with multi-cancer early detection tests offers a closer look at how this approach may be shaping aspects of preventive healthcare. In the context of this MCED article, we
K-TRACK Performance Validated in JTO Clinical and Research Reports: A Direct Comparison of Tumor‑Informed and Tumor‑Naïve ctDNA‑MRD Testing in Early‑Stage NSCLC
Gene Solutions is pleased to announce the publication of our latest research in JTO Clinical and Research Reports, evaluating the K-TRACK portfolio entitled: “Direct Comparison of Tumor-Informed and Tumor-Naïve ctDNA
Two Best Poster Awards at ESMO Asia 2025
This year at ESMO Asia 2025 in Singapore, the R&D team from Gene Solutions was honored with two Best Poster Awards — recognition that reflects not only scientific excellence, but
Bridging Genomic Insights: AI‑Powered Liquid Biopsy and Multi‑Omics at ESMO Asia Congress 2025
At ESMO Asia Congress 2025 (December 5–7), Gene Solutions’ Industry Satellite Symposium brought together leading voices from across the region to examine how AI-driven liquid biopsy and multi‑omics are reshaping
Gene Solutions at POGS 2025: Advancing Precision & Preventive Care
PUNE, INDIA — December 2025 — Gene Solutions was proud to participate in the 34th Annual Conference of the Pune Obstetrics and Gynecology Society (POGS) and welcomed more than 310
02
Press release
World Cancer Day: Genomics & AI Blood Test Detects Cancer Before Symptoms Appear in India
Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.
Key finding:
IRVINE, Calif., Jan. 21, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests (LDTs), announced a strategic collaboration to advance U.S. verification and clinical validation of liquid biopsy assays designed for cancer detection, profiling, and monitoring.Authors:
Gene Solutions Genomics Pte Ltd
Gene Solutions Concludes Successful ESMO Asia Congress 2025 with AI-Powered Multi-Omics Liquid Biopsy Symposium and Two Best Poster Awards
Key finding:
SINGAPORE, Dec. 20, 2025 /PRNewswire/ — Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medical Oncology (ESMO) Asia Congress 2025—held in Singapore on December 5–7. Highlights included a full-house symposium, seven scientific abstracts with two earning Best Poster designations, and meaningful engagement with thousands of oncologists from across the Asia-Pacific region at the company’s exhibition booth.Authors:
Gene Solutions Genomics Pte Ltd
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Key finding:
TAIPEI, Nov. 28, 2025 /PRNewswire/ — Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement with the introduction of SPOT-MAS – an advanced screening solution developed by Gene Solutions, a global leader in precision oncology and genomics, in collaboration with local partner Gene Health.Authors:
Gene Solutions Genomics Pte Ltd
AI and Multi-omics are Transforming Cancer Care: APAC Precision Oncology Conference Outlines the Future of Early Detection and Personalized Treatment
Key finding:
HONG KONG, Nov. 17, 2025 /PRNewswire/ — The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in Cancer Management, convened in Hong Kong on November 1, marking Lung Cancer Awareness Month with a clear message: AI and multi-omics are no longer theoretical – they are driving real-world advancements in cancer care across the Asia-Pacific (APAC) region.Authors:
Gene Solutions Genomics Pte Ltd
Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials
Key finding:
Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant milestone in advancing precision medicine in Southeast Asia.Authors:
Gene Solutions Genomics Pte Ltd
Gene Solutions Brings Insights on Advances in MRD and Multi-Omics Technologies to the Singapore Society of Oncology Annual Scientific Meeting 2025
Key finding:
At the Singapore Society of Oncology Annual Scientific Meeting 2025 (SSO ASM 2025), Gene Solutions showcased how Molecular Residual Disease (MRD) and AI-powered multi-omics technologies are advancing precision oncology across Asia-Pacific, reinforcing Singapore’s role as a hub for innovation and global collaboration.Authors:
Gene Solutions Genomics Pte Ltd
Gene Solutions and AMPATH Launch Advanced Genomics Laboratory in Hyderabad to Expand Access to Precision Medicine in India
Authors:
Gene Solutions Genomics Pte Ltd
Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China
Key finding:
Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular diagnostics, have entered a strategic partnership through a Memorandum of Understanding (MOU).Authors:
Gene Solutions Genomics Pte Ltd
Gene Solutions and Topgen Join Forces to Advance Precision Oncology All Over China
Key finding:
Gene Solutions has formalized a strategic collaboration with Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd., a CAP-accredited laboratory with a well-established footprint across all over China.Authors:
Gene Solutions Genomics Pte Ltd
Illuminating ctDNA-MRD: Gene Solutions’ K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology
Key finding:
Gene Solutions, a pioneer in AI-driven precision oncology hosted K-CONNECT APAC 2025, a pivotal summit uniting over 100 distinguished oncologists and molecular biologists from nine Asia-Pacific countries. — This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor DNA (ctDNA), Molecular Residual Disease (MRD), and Comprehensive Genomic Profiling (CGP).Authors:
Gene Solutions Genomics Pte Ltd
SPOT-MAS Lung: AI-Powered Blood Test Brings New Hope to High-Risk Non-Smokers in Asia
Authors:
Gene Solutions Genomics Pte Ltd
